肺癌患者痰液端粒酶活性检测的临床研究  

THE CLINICAL RESEARCH OF TELOMERASE ACTIVITY IN SPUTUM OF LUNG CANCER PATIENTS

作　　者：胡坚[1] 李任远[1] 孙鹂[2] 倪一鸣[1] 

机构地区：[1]浙江大学医学院附属第一医院心胸外科,浙江杭州310003 [2]杭州师范学院医学院科研实验室,浙江杭州310012

出　　处：《癌变．畸变．突变》2003年第4期223-225,共3页Carcinogenesis,Teratogenesis & Mutagenesis

基　　金：浙江省教育厅基金(No.19990518)

摘　　要：目的 :分析研究肺癌患者痰液端粒酶活性表达的临床意义。 方法 :运用端粒酶PCR -TRAP酶联免疫吸附试验(ELISA)测定法对30例肺癌患者及25例肺部良性疾病患者(对照组)的痰液进行端粒酶活性检测。 结果 :肺癌患者痰液标本中端粒酶活性阳性率为56.7 %(17/30) ,肺部良性疾病患者(对照组)的痰液标本端粒酶活性阳性率为24 %(6/25) ,二者经统计学处理 ,有显著性差异(P<0.05)。 结论 :检测肺癌患者痰液端粒酶活性有助于肺癌与其它良性肺部疾病的诊断及鉴别诊断 ,且具有方法相对简便、无创。Purpose: To study the clinical significance of the expression of telomerase activity in sputa of lung cancer patients. Methods: The sputa of 30 lung cancer patients and 25 benign lung disease patients(control group) were checked for telomerase activity with PCR-TRAP ELISA. Results: The positive rates of telomerase activity in sputum was 56.7 %(17/30) in lung cancer group and 24 %(6 /25) in control group. The difference is statistically significant(P< 0.05). Conclusion: The detection of telomerase activity in sputum of lung cancer patient is helpful for not only the diagnosis of lung cancer but also the differential diagnosis with other benign lung diseases. The assay method is comparatively convenient and nontraumatic, and the specimen is easy to collect.

关 键 词：肺肿瘤 痰标本 端粒酶活性 

分 类 号：R730.4[医药卫生—肿瘤]